Literature DB >> 8538348

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.

S Vento1, F Cainelli, F Mirandola, L Cosco, G Di Perri, M Solbiati, T Ferraro, E Concia.   

Abstract

BACKGROUND: Fulminant hepatitis on withdrawal of chemotherapy has been described in chronic hepatitis B virus infection, but not in hepatitis C virus (HCV) infection. The relation between HCV and immune response to this virus, and disease severity, has not been examined. We present two patients with HCV who developed fulminant liver failure after chemotherapy was stopped. PATIENTS AND
FINDINGS: Two patients with chronic HCV infection and malignant lymphoma received chemotherapy (cyclophosphamide, adriamycin, vincristine, bleomycin, etoposide, and prednisolone in patient 1; doxorubicin, bleomycin, vinblastine, and dacarbazine in patient 2), on withdrawal of which both developed fulminant hepatitis. Alanine aminotransferase (ALT) concentrations were greatly raised (6030 and 3870 IU/L in patients 1 and 2, respectively), and serum HCV-RNA was low in both patients when severe disease developed (10(2) genome equivalents per mL). Patient 1 died, and necropsy showed massive liver necrosis.
INTERPRETATION: The findings suggest an immune-mediated mechanism for hepatocyte damage in HCV infection. Careful monitoring of ALT concentrations is necessary in such patients during and after chemotherapy.

Entities:  

Mesh:

Year:  1996        PMID: 8538348     DOI: 10.1016/s0140-6736(96)90212-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way.

Authors:  Harrys A Torres; Javier A Adachi; Lillian R Roach; Kathleen M Smith; Parag S Mahale; Marta Davila; Issam I Raad
Journal:  Clin Infect Dis       Date:  2012-03-01       Impact factor: 9.079

Review 2.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Authors:  Harrys A Torres; Marta Davila
Journal:  Nat Rev Clin Oncol       Date:  2012-01-24       Impact factor: 66.675

3.  The effect of transcatheter arterial chemoembolization on hepatitis C viremia.

Authors:  Parag Mahale; Ahmed Kaseb; Marta Davila; Harrys A Torres
Journal:  Oncologist       Date:  2012

Review 4.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 5.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

6.  Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia.

Authors:  K Ishiga; T Kawatani; T Suou; F Tajima; H Omura; Y Idobe; H Kawasaki
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

7.  Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.

Authors:  Harrys A Torres; Jeff Hosry; Parag Mahale; Minas P Economides; Ying Jiang; Anna S Lok
Journal:  Hepatology       Date:  2017-11-13       Impact factor: 17.425

8.  The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.

Authors:  Jawad Ahmad; John Rhee; Brian I Carr
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

10.  Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

Authors:  Takeaki Takenaka; Kuniaki Itoh; Takayo Suzuki; Atae Utsunomiya; Shin Matsuda; Takaaki Chou; Toshiaki Sai; Masayuki Sano; Susumu Konda; Tatsuji Ohno; Chikara Mikuni; Kijoh Deura; Takashi Yamada; Fumi Mizorogi; Haruhisa Nagoshi; Masao Tomonaga; Tomomitsu Hotta; Kohichi Kawano; Keitaro Tsushita; Masami Hirano; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.